AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT06388616
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT06386263
- Locations
- 🇨🇦
Research Site, Oakville, Ontario, Canada
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
Recruiting
- Conditions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT06380738
- Locations
- 🇩🇪
Research Site, Wetzlar, Germany
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 96
- Registration Number
- NCT06381466
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT06380751
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.
Recruiting
- Conditions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT06376097
- Locations
- 🇧🇷
Hospital das Clínicas da Faculdade de Medicina de Botucatu (HCFMB), Botucatu, São Paulo, Brazil
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 700
- Registration Number
- NCT06376084
- Locations
- 🇨🇳
Research Site, Shanghai, China
PRospectIve ObseRvatIonal mulTicenter Study of Patients With Arterial hYpertension and CKD in the Population of Russia
Recruiting
- Conditions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10000
- Registration Number
- NCT06372431
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT06368427
- Locations
- 🇷🇴
Research Site, Timisoara, Romania
A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT06368440
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
© Copyright 2024. All Rights Reserved by MedPath